Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 1
2016 1
2019 1
2020 2
2021 2
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Proceedings of the 3rd IPLeiria's International Health Congress : Leiria, Portugal. 6-7 May 2016.
Tomás CC, Oliveira E, Sousa D, Uba-Chupel M, Furtado G, Rocha C, Teixeira A, Ferreira P, Alves C, Gisin S, Catarino E, Carvalho N, Coucelo T, Bonfim L, Silva C, Franco D, González JA, Jardim HG, Silva R, Baixinho CL, Presado MªH, Marques MªF, Cardoso ME, Cunha M, Mendes J, Xavier A, Galhardo A, Couto M, Frade JG, Nunes C, Mesquita JR, Nascimento MS, Gonçalves G, Castro C, Mártires A, Monteiro MªJ, Rainho C, Caballero FP, Monago FM, Guerrero JT, Monago RM, Trigo AP, Gutierrez ML, Milanés GM, Reina MG, Villanueva AG, Piñero AS, Aliseda IR, Ramirez FB, Ribeiro A, Quelhas A, Manso C, Caballero FP, Guerrero JT, Monago FM, Santos RB, Jimenez NR, Nuñez CG, Gomez IR, Fernandez MªJL, Marquez LA, Moreno AL, Huertas MªJT, Ramirez FB, Seabra D, Salvador MªC, Braga L, Parreira P, Salgueiro-Oliveira A, Arreguy-Sena C, Oliveira BF, Henriques MªA, Santos J, Lebre S, Marques A, Festas C, Rodrigues S, Ribeiro A, Lumini J, Figueiredo AG, Hernandez-Martinez FJ, Campi L, Quintana-Montesdeoca MªP, Jimenez-Diaz JF, Rodriguez-De-Vera BC, Parente A, Mata MªA, Pereira AMª, Fernandes A, Brás M, Pinto MªR, Parreira P, Basto ML, Rei AC, Mónico LM, Sousa G, Morna C, Freitas O, Freitas G, Jardim A, Vasconcelos … See abstract for full author list ➔ Tomás CC, et al. BMC Health Serv Res. 2016 Jul 6;16 Suppl 3(Suppl 3):200. doi: 10.1186/s12913-016-1423-5. BMC Health Serv Res. 2016. PMID: 27409075 Free PMC article.
Gomez, M Jose L. Fernandez, Laura A. Marquez, Ana L. Moreno, M Jesus Tena Huertas, Francisco B. ...Guerrero, Francisco P. Caballero, Rafael B. Santos, Estefania P. Gonzalez, Fatima M. Monago, Lierni U. Ugalde, Marta M. ...
Gomez, M Jose L. Fernandez, Laura A. Marquez, Ana L. Moreno, M Jesus Tena Huertas, Francisco B. ...Guerrero, Francisco …
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, Campbell SE, Oshima R, Amarenco P, Blom DJ, Brinton EA, Eckel RH, Elam MB, Felicio JS, Ginsberg HN, Goudev A, Ishibashi S, Joseph J, Kodama T, Koenig W, Leiter LA, Lorenzatti AJ, Mankovsky B, Marx N, Nordestgaard BG, Páll D, Ray KK, Santos RD, Soran H, Susekov A, Tendera M, Yokote K, Paynter NP, Buring JE, Libby P, Ridker PM; PROMINENT Investigators. Das Pradhan A, et al. N Engl J Med. 2022 Nov 24;387(21):1923-1934. doi: 10.1056/NEJMoa2210645. Epub 2022 Nov 5. N Engl J Med. 2022. PMID: 36342113 Clinical Trial.
As compared with placebo, the effects of pemafibrate on lipid levels at 4 months were -26.2% for triglycerides, -25.8% for very-low-density lipoprotein (VLDL) cholesterol, -25.6% for remnant cholesterol (cholesterol transported in triglyceride-rich lipoproteins after lipolysis an …
As compared with placebo, the effects of pemafibrate on lipid levels at 4 months were -26.2% for triglycerides, -25.8% for very-low-density …
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Salloway S, et al. N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839. N Engl J Med. 2014. PMID: 24450891 Free PMC article. Clinical Trial.
Secondary outcome measures included findings on positron-emission tomographic amyloid imaging with the use of Pittsburgh compound B (PIB-PET) and cerebrospinal fluid phosphorylated tau (phospho-tau) concentrations. ...
Secondary outcome measures included findings on positron-emission tomographic amyloid imaging with the use of Pittsburgh compound B ( …
Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2015 and GOLD 2019 staging: a pooled analysis of individual patient data.
García Castillo E, Alonso Pérez T, Ancochea J, Pastor Sanz MT, Almagro P, Martínez-Camblor P, Miravitlles M, Rodríguez-Carballeira M, Navarro A, Lamprecht B, Ramírez-García Luna AS, Kaiser B, Alfageme I, Casanova C, Esteban C, Soler-Cataluña JJ, de-Torres JP, Celli BR, Marín JM, Ter Riet G, Sobradillo P, Lange P, Garcia-Aymerich J, Anto JM, Turner AM, Han MK, Langhammer A, Vikjord SAA, Sternberg A, Leivseth L, Bakke P, Johannessen A, Oga T, Cosío BG, Echazarreta A, Roche N, Burgel PR, Sin DD, Puhan MA, López-Campos JL, Carrasco L, Soriano JB. García Castillo E, et al. ERJ Open Res. 2020 Nov 2;6(4):00253-2020. doi: 10.1183/23120541.00253-2020. eCollection 2020 Oct. ERJ Open Res. 2020. PMID: 33263033 Free PMC article.
For both classifications, group D had higher mortality. 5-year mortality did not differ between groups B and C in GOLD 2015; in GOLD 2019, mortality was greater for group B than C. Patients classified as group A and B had better sensitivity and …
For both classifications, group D had higher mortality. 5-year mortality did not differ between groups B and C in GOLD 2015; i …
Antibacterial activity of 3,3'-dihydroxycurcumin (DHC) is associated with membrane perturbation.
Polaquini CR, Morão LG, Nazaré AC, Torrezan GS, Dilarri G, Cavalca LB, Campos DL, Silva IC, Pereira JA, Scheffers DJ, Duque C, Pavan FR, Ferreira H, Regasini LO. Polaquini CR, et al. Bioorg Chem. 2019 Sep;90:103031. doi: 10.1016/j.bioorg.2019.103031. Epub 2019 Jun 7. Bioorg Chem. 2019. PMID: 31238181
In this work, we evaluated the antimicrobial activity of diphenylheptanoids derived from curcumin against Gram-positive and Gram-negative bacteria, and also against Mycobacterium tuberculosis in terms of MIC (Minimum Inhibitory Concentration) and MBC (Minimum Bactericidal Concent …
In this work, we evaluated the antimicrobial activity of diphenylheptanoids derived from curcumin against Gram-positive and Gram-negative ba …
Efficacy and safety of glecaprevir/pibrentasvir in treatment-naive adults with chronic hepatitis C virus genotypes 1-6 in Brazil.
Peribañez-Gonzalez M, Cheinquer H, Rodrigues L, Lima MP, Álvares-da-Silva MR, Madruga J, Parise ER, Pessoa MG, Furtado J, Villanova M, Ferreira A, Mazzoleni F, Nascimento E, Silva GF, Fredrick L, Krishnan P, Burroughs M, Reuter T. Peribañez-Gonzalez M, et al. Ann Hepatol. 2021 Jan-Feb;20:100257. doi: 10.1016/j.aohep.2020.09.002. Epub 2020 Sep 17. Ann Hepatol. 2021. PMID: 32949786 Free article. Clinical Trial.
INTRODUCTION AND OBJECTIVES: Glecaprevir/pibrentasvir is a highly effective and well tolerated treatment for hepatitis C infection. Brazilian patients were not included in the original development studies for glecaprevir/pibrentasvir. ...CONCLUSIONS: Glecaprevir/pibrentasv …
INTRODUCTION AND OBJECTIVES: Glecaprevir/pibrentasvir is a highly effective and well tolerated treatment for hepatitis C infection. B …
Antibacterial activity of a new monocarbonyl analog of curcumin MAC 4 is associated with divisome disruption.
Polaquini CR, Marques BC, Ayusso GM, Morão LG, Sardi JCO, Campos DL, Silva IC, Cavalca LB, Scheffers DJ, Rosalen PL, Pavan FR, Ferreira H, Regasini LO. Polaquini CR, et al. Bioorg Chem. 2021 Apr;109:104668. doi: 10.1016/j.bioorg.2021.104668. Epub 2021 Jan 27. Bioorg Chem. 2021. PMID: 33601139
Phenolic MACs 4, 6 and 8 showed a broad spectrum and potent activity, mainly against M. tuberculosis, Acinetobacter baumannii and methicillin-resistant Staphylococcus aureus (MRSA), with MIC (minimum inhibitory concentration) values ranging from 0.9 to 15.6 g/mL. ...Howeve …
Phenolic MACs 4, 6 and 8 showed a broad spectrum and potent activity, mainly against M. tuberculosis, Acinetobacter baumannii and met …
Physical Growth, Biological Age, and Nutritional Transitions of Adolescents Living at Moderate Altitudes in Peru.
Cossio-Bolaños M, Campos RG, Andruske CL, Flores AV, Luarte-Rocha C, Olivares PR, Garcia-Rubio J, de Arruda M. Cossio-Bolaños M, et al. Int J Environ Res Public Health. 2015 Sep 25;12(10):12082-94. doi: 10.3390/ijerph121012082. Int J Environ Res Public Health. 2015. PMID: 26404334 Free PMC article.
OBJECTIVES: The objectives of this study were the following: (a) compare physical growth patterns with an international standard; (b) determine biological age; and (c) analyze the double nutritional burden of adolescents living at a moderate altitude in Peru. DESIGN …
OBJECTIVES: The objectives of this study were the following: (a) compare physical growth patterns with an international standard; (b) …